. Author manuscript; available in PMC: 2013 May 1.

Published in final edited form as: J Matern Fetal Neonatal Med. 2011 Aug 25;25(5):498–507. doi: 10.3109/14767058.2011.591461

Table II.

Maternal plasma concentration of angiongenic and antiangiogenic factors in the study population

	Uncomplicated Pregnancy (n=64)	Preeclampsia without placental lesions of underperfusion (n= 35)	Preeclampsia with placental lesions of underperfusion (n=31)

PlGF(pg/ml)	348.8 (196.3–729.3)	128.9 (85–212)^†	90 (68–137)^*^†
PlGF/sVEGFR-1	0.23 (0.11–0.43)	0.029 (0.020–0.048)^†	0.017 (0.10–0.26)^*^†
PlGF/sEng	49.2 (17.2–96)	6.7 (1.9–13.1)^†	2.3 (1.5–6)^*^†
sEng(ng/ml)	8.1 (6.1–12.5)	20.6 (12–40.7)^†	35.5 (15–49.2)^†
sVEGFR-1(pg/ml)	1635 (1150–2138)	3995 (3058–5679)^†	5314 (3404–8231)^†
sVEGFR-2(ng/ml)	9.2 (7.4–11.2)	7 (5.4–8.5)^†	7.5 (5.6–10.5)

Values expressed as median (interquartile range)

PE: Preeclampsia; PlGF: placental growth factor; sEng: soluble endoglin;

sVEGFR-1: soluble vascular endothelial growth factor receptor 1

sVEGFR-2: soluble vascular endothelial growth factor receptor 2

p-value <0.05 when compared to late-onset PE without placental lesions of underperfusion.

^†

p-value <0.01 when compared to normal pregnancy